A qualitative study among injection drug using women in Rhode Island: Attitudes toward testing, treatment, and vaccination for hepatitis and HIV

AIDS Patient Care and STDs

Volumn 22, Issue 1, 2008, Pages 53-63

  Lally, Michelle A ^a   Montstream Quas, Sydney A ^a   Tanaka, Sara ^a   Tedeschi, Sara K ^a   Morrow, Kathleen M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATTITUDE TO HEALTH; DRUG USE; FEMALE; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEPATITIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PSYCHOLOGICAL ASPECT; QUALITATIVE ANALYSIS; STIGMA; UNITED STATES; VACCINATION;

ADULT; AIDS SERODIAGNOSIS; ATTITUDE TO HEALTH; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; SUBSTANCE ABUSE, INTRAVENOUS; VACCINATION;

EID: 38149032629     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.0206     Document Type: Article

References (38)

1. AIDS Cases by Exposure Category. www.cdc.gov/hiv/stats.htm. (Last accessed August 19, 2005).
2. HIV diagnoses among injection-drug users in states with HIV surveillance - 25 States, 1994-2000. www.cdc.gov/mmwr/preview/mmwrhtml/mm5227a2.htm. MMWR 2003;52:634-636. (Last accessed November 4, 2005).
3. Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: Patient and treatment considerations. Clin Gastroenterol Hepatol 2005;3:311-318.
4. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S6-10.
5. Lorvick J, Kral AH, Seal K, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001;91:46-47.
6. Aceijas C, Stimson GV, Hickman M, Rhodes T, United Nations Reference Group on HIV/AIDS Prevention and Care among IDU in Developing and Transitional Countries. Global overview of injecting drug use and HIV infection among injecting drug users." AIDS 2004;18:2295-2303.
7. Wasley A, Miller J, Finelli L. Surveillance for acute viral hepatitis - United States, 2005. MMWR 2007;56:1-24.
8. Appel PW, Ellison AA, Jansky HK, Oldak R. Barriers to enrollment in drug abuse treatment and suggestions for reducing them: Opinions of drug injecting street outreach clients and other system stakeholders. Am J Drug Alcohol Abuse 2004;30:129-153.
9. Knowlton AR. Access to Medical Care and service utilization among injection drug users with HIV/AIDS. Drug Alcohol Depend 2001;64:55-62.
10. www.cdc.gov/idu/hepatitis/vaccines.htm. (Last accessed August 19, 2005).
11. Lundgren L, Chassler D, Ben-Ami L, Purington T, Schilling R. Factors associated with emergency room use among injection drug users of African-American, Hispanic and white European background. Am J Addict 2005;14:268-280.
12. Centers for Disease Control and Prevention, National Center for Infectious Diseases, Division of Viral Hepatitis. National Hepatitis C Prevention Strategy: A Comprehensive Strategy for the Prevention and Control of Hepatitis C Virus Infection and Its Consequences. 2001.
13. Heimer H, Clair S, Grau L, Bluthenthal RN, Marshall PA, Singer M. Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction 2002;97:1277-1287.
14. Kuo I, Sherman SG, Thomas DL, Strathdee SA. Hepatitis B virus infection and vaccination among young injection and non-injection drug users: Missed opportunities to prevent infection. Drug Alcohol Depend 2004;73:69-78.
15. Sylvestre DL. Treating hepatitis C virus infection in active substance users. Clin Infect Dis 2005;40:S321-324.
16. Krain A, Wisnivesky JP, Garland E, McGinn T. Prevalence of human immunodeficiency virus testing in patients with hepatitis B and C infection. Mayo Clin Proc 2004;79:51-56.
17. Sullivan PS, Lansky A, Drake A, HITS-2000 Investigators. Failure to return for HIV test results among persons at high risk for HIV infection: Results from a multistate interview project. J Acquir Immune Defic Syndr 2004;35:511-518.
18. McGarry KA, Stein MD, Clarke JG, Friedmann PD. Utilization of preventive health services by HIV-seronegative injection drug users. J Addict Dis 2002;21:93-102.
19. Valdiserri RO, Jones TS, West GR, Campbell CH Jr, Thompson PI. Where injecting drug users receive HIV counseling and testing. Public Health Rep 1993;108:294-298.
20. Koester S. Applying the methodology of participant observation to the study to injection-related HIV risks. In: U.S. Department of Health and Human Services, Qualitative Methods in Drug Abuse and HIV Research. NIDA Res Monogr 1995;157:84-99.
21. Downing M, Knight K, Reiss TH, et al. Drug users talk about HIV testing: Motivating and deterring factors. AIDS Care 2001;13:561-577.
22. Small W, Kain S, Laliberte N, Schechter MT, O'Shaughnessy MV, Spittal PM. Incarceration, addiction and harm reduction: Inmates experience injecting drugs in prison. Subst Use Misuse, 2005;40:831-843.
23. Knight KR, Purcell D, Dawson-Rose C, Halkitis PN, Gomez CA. Sexual risk taking among HIV-positive injection drug users: Contexts, characteristics, and implications for prevention. AIDS Educ Prev 2005;17:76-88.
24. Patton MQ. Enhancing the quality and credibility of qualitative analysis. Health Serv Res 1999;3:1189-1208.
25. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001;61:211-215.
26. Carey J, Perlman DC, Friedmann P, et al. Knowledge of hepatitis among active drug injectors at a syringe exchange program. J Subst Abuse Treat 2005;29:47-53.
27. Morrow K, Costello T, Boland R. Understanding the psychosocial needs of HIV-positive women: A qualitative study. Psychosomatics 2001;42:497-503.
28. Spielberg F, Kurth A, Gorbach PM, Goldbaum G. Moving form apprehension to action: HIV counseling and testing preferences in three at-risk populations. AIDS Educ Prev 2001;13:524-540.
29. Bond L, Lauby J, Batson H. HIV testing and the roles of the individual- and structural-level barriers and facilitators. AIDS Care 2005;17:125-140.
30. Patton MQ. Qualitative Evaluation and Research Methods. Newbury Park, CA: Sage Publications, 1990.
31. Goldstein MF, Friedman SR, Neaigus A, et al. Self-reports of HIV risk behavior by injecting drug users: are they reliable. Addiction 1995;90:1097-1104.
32. Needle R, Weatherby N, Chitwood D, et al. Reliability of self-reported HIV risk behaviors of drug users. Psychol Addict Behav 1995;9:242-250.
33. Vlahov D, Polk BF. Perspectives on infection with HIV-1 among intravenous drug users. Psychopharmacol Bull 1998;24:325-329.
34. Harrison LD. The validity of self-reported data on drug use. J Drug Issues 1995;25:91-111.
35. Macalino GE, Celentano DD, Latkin C, Strathdee SA, Vlahov D. Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev 2002;14:367-378.
36. Lawless, S. (1998). Barriers to accessing treatments for women living with HIV/AIDS: a difference of opinion [Abstract 421313]. Intl Conf AIDS 1998;12:836.
37. Murphy DA, Marelich WD, Dello Stritto ME, Swendenman D, Witkin A. Mothers living with HIV/AIDS: mental, physical, family functioning. AIDS Care 2002;14:633-644.
38. Lally MA, MacNevin R, Sergie Z, et al. A model to provide comprehensive testing for HIV, viral hepatitis, and sexually transmitted infections at a short-term drug treatment center. AIDS Patient Care STDs 2005;19:298-305.